IGF1R and lung carcinoma: We did not observe a higher grade 5 toxicity in the experimental arm, implying that there may be a difference of these antibodies, chemotherapy used, or lack of maintenance therapy with D. Unfortunately, we cannot clarify these questions since IGF-1R class of drug is no longer in the development of lung cancer.